Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: Part 3. Biomarkers of biological effect

Michael W Ogden, Kristin M Marano, Bobbette A Jones, Walter T Morgan, Mitchell F Stiles, Michael W Ogden, Kristin M Marano, Bobbette A Jones, Walter T Morgan, Mitchell F Stiles

Abstract

A randomized, multi-center study of adult cigarette smokers switched to tobacco-heating cigarettes, snus or ultra-low machine yield tobacco-burning cigarettes (50/group) for 24 weeks was conducted. Evaluation of biomarkers of biological effect (e.g. inflammation, lipids, hypercoaguable state) indicated that the majority of consistent and statistically significant improvements over time within each group were observed in markers of inflammation. Consistent and statistically significant differences in pairwise comparisons between product groups were not observed. These findings are relevant to the understanding of biomarkers of biological effect related to cigarette smoking as well as the risk continuum across various tobacco products (ClinicalTrials.gov Identifier: NCT02061917).

Keywords: Inflammation; multi-center randomized study; oxidative stress; risk continuum.

Figures

Figure 1.
Figure 1.
Percent change in sICAM1 over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significant reduction (p<0.05) from week 0.
Figure 2.
Figure 2.
Percent change in WBC over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significant reduction (p<0.05) from week 0.
Figure 3.
Figure 3.
Percent change in SCE mean events over time in smokers switched to tobacco-heating cigarettes (TH), snus or ultra-low machine yield tobacco-burning cigarettes (TB). *Statistically significant difference (p<0.05) from week 0.

References

    1. Adhikari B, Kahende J, Malarcher A, et al. Smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 2000–2004. MMWR. 2008;57:1226–8.
    1. Bolinder G, Norén A, de Faire U, Wahren J. Smokeless tobacco use and atherosclerosis: an ultrasonographic investigation of carotid intima media thickness in healthy middle-aged men. Atherosclerosis. 1997;132:95–103.
    1. Borgerding MF, Bodnar JA, Curtin GM, Swauger JE. The chemical composition of smokeless tobacco: a survey of products sold in the United States in 2006 and 2007. Regul Toxicol Pharmacol. 2012;64:367–87.
    1. Calapai G, Caputi AP, Mannucci C, et al. A cross-sectional investigation of biomarkers of risk after a decade of smoking. Inhal Toxicol. 2009;21:1138–43.
    1. Eliasson M, Lundblad D, Hägg E. Cardiovascular risk factors in young snuff-users and cigarette smokers. J Intern Med. 1991;230:17–22.
    1. Frost-Pineda K, Liang Q, Liu J, et al. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob Res. 2011;13:182–93.
    1. Hatsukami DK, Benowitz NL, Rennard SI, et al. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob Res. 2006;8:600–22.
    1. Goto K, Maeda S, Kano Y, Sugiyama T. Factors involved in differential Giemsa-staining of sister chromatids. Nature. 1978;251:156–8.
    1. Henley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control. 2007;16:22–8.
    1. International Conference on Harmonization (ICH). 1996.
    1. Kondo T, Hayashi M, Takeshita K, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. Arterioscler Thromb Vasc Biol. 2004;24:1442–7.
    1. Latt SA. Sister chromatid exchanges, indices of human chromosome damage and repair: Detection by fluorescence and induction by mitomycin C. Proc Natl Acad Sci USA. 1974;71:3162–6.
    1. Lee PN. Summary of the epidemiological evidence relating snus to health. Regul Toxicol Pharmacol. 2011;59:197–214.
    1. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev. 2004;13:2035–42.
    1. Lowe FJ, Gregg EO, McEwan M. Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers. Clin Chem Lab Med. 2009;47:311–20.
    1. Lowe FJ, Luettich K, Gregg EO. Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers. 2013;18:183–95.
    1. Marano KM, Kathman SJ, Jones BA, et al. Study of cardiovascular disease biomarkers among tobacco consumers. Part 3: evaluation and comparison with the US National Health and Nutrition Examination Survey. Inhal Toxicol. 2015;27:167–73.
    1. Marano KM, Naufal ZS, Borgerding MB, Potts RJ. Quantitative risk assessment of tobacco-burning and tobacco-heating cigarettes. Rec Adv Tob Sci. 2012;38:3–20.
    1. Nordskog BK, Brown BG, Marano KM, et al. Study of cardiovascular disease biomarkers among tobacco consumers, part 2: biomarkers of biological effect. Inhal Toxicol. 2015;27:157–66.
    1. Nutt DJ, Phillips LD, Balfour D, et al. Estimating the harms of nicotine-containing products using the MCDA approach. Eur Addict Res. 2014;20:218–25.
    1. OECD. Genetic toxicology: in vitro sister chromatid exchange assay in mammalian cells. Paris: Organization for Economic Co-Operation and Development; 1986. p. 479.
    1. Ogden MW, Marano KM, Jones BA, Stiles MF. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 1. Study design and methodology; 2015a.
    1. Ogden MW, Marano KM, Jones BA, et al. Switching from usual brand cigarettes to a tobacco-heating cigarette or snus: part 2. Biomarkers of exposure; 2015b.
    1. Rennard SI, Daughton D, Fujita J, et al. Short-term smoking reduction is associated with reduction in measures of lower respiratory tract inflammation in heavy smokers. Eur Respir J. 1990;3:752–9.
    1. Rennard SI, Umino T, Millatmal T, et al. Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device that primarily heats tobacco. Nicotine Tob Res. 2002;4:467–76.
    1. Roth HD, Roth AB, Liu X. Health risks of smoking compared to Swedish snus. Inhal Toxicol. 2005;17:741–8.
    1. R.J. Reynolds Tobacco Company (RJRT) and American Snuff Company, LLC (ASC). 2011. July. 28.
    1. R.J. Reynolds Tobacco Company (RJRT). 2012. August. 21.
    1. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: the science base for tobacco harm reduction-executive summary. Tob Control. 2001;10:189–95.
    1. Tonstad S, Cowan JL. C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract. 2009;63:1634–41.
    1. US Department of Health and Human Services. (USDHHS) How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2010.
    1. Wagner BM. Eclipse Expert Panel. A safer cigarette? A comparative study. A consensus report. Inhal Toxicol. 2000;12:1–48.
    1. Yan W, Byrd GD, Ogden MW. Determination of isoprostanes in urine from smokers and never smokers by liquid chromatography tandem mass spectrometry. 54th Annual Conference on Mass Spectrometry and Allied Topics; Seattle, WA: 2006.
    1. Zeller M, Hatsukami D. Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control. 2009;18:324–32.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir